Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E, Dugo M, Cossa M, Frigerio S, Di Guardo L, Gallino G, Mattavelli I, Vergani B, Lalli L, Tamborini E, Valeri B, Gargiuli C, Shahaj E, Ferrarini M, Ferrero E, Gomez Lira M, Huber V, Del Vecchio M, Sensi M, Leone BE, Santinami M, Rivoltini L, Rodolfo M, Vallacchi V. Vergani E, et al. Among authors: dugo m. Cell Commun Signal. 2020 Sep 23;18(1):156. doi: 10.1186/s12964-020-00601-1. Cell Commun Signal. 2020. PMID: 32967672 Free PMC article.
Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.
Huang X, Dugo M, Callari M, Sandri M, De Cecco L, Valeri B, Carcangiu ML, Xue J, Bi R, Veneroni S, Daidone MG, Ménard S, Tagliabue E, Shao Z, Wu J, Orlandi R. Huang X, et al. Among authors: dugo m. Cancer Med. 2015 Jul;4(7):1016-30. doi: 10.1002/cam4.442. Epub 2015 Mar 18. Cancer Med. 2015. PMID: 25787708 Free PMC article.
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, De Braud F, Rivoltini L, Rodolfo M. Vergani E, et al. Among authors: dugo m. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599. Oncotarget. 2016. PMID: 26684239 Free PMC article.
microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.
Vallacchi V, Camisaschi C, Dugo M, Vergani E, Deho P, Gualeni A, Huber V, Gloghini A, Maurichi A, Santinami M, Sensi M, Castelli C, Rivoltini L, Rodolfo M. Vallacchi V, et al. Among authors: dugo m. Genes (Basel). 2016 Dec 14;7(12):124. doi: 10.3390/genes7120124. Genes (Basel). 2016. PMID: 27983661 Free PMC article.
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.
Huber V, Vallacchi V, Fleming V, Hu X, Cova A, Dugo M, Shahaj E, Sulsenti R, Vergani E, Filipazzi P, De Laurentiis A, Lalli L, Di Guardo L, Patuzzo R, Vergani B, Casiraghi E, Cossa M, Gualeni A, Bollati V, Arienti F, De Braud F, Mariani L, Villa A, Altevogt P, Umansky V, Rodolfo M, Rivoltini L. Huber V, et al. Among authors: dugo m. J Clin Invest. 2018 Dec 3;128(12):5505-5516. doi: 10.1172/JCI98060. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260323 Free PMC article.
The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.
Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S. Devecchi A, et al. Among authors: dugo m. Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3. Cancer Commun (Lond). 2018. PMID: 30486883 Free PMC article.
120 results